secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001193125-24-195895
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea reports Q2 net loss $40.5M; Phase 2 HCV data show 97% SVR12; Phase 3 COVID-19 trial due 2H24
--------------------------------------------------------------------------------

- Net loss of $40.5M for Q2 2024 (diluted EPS -$0.48) vs $28.2M loss in Q2 2023; cash balance $502.2M.
- R&D expenses rose to $34.7M (+$12.6M YoY) driven by Phase 2/3 trial costs.
- Full enrollment in global Phase 2 HCV study (bemnifosbuvir + ruzasvir); SVR12 results expected 4Q 2024.
- Lead-in cohort (n=60) at EASL achieved 97% SVR12 with 8-week treatment; no drug-related serious AEs.
- Phase 3 SUNRISE-3 (bemnifosbuvir for COVID-19) topline data anticipated in 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312524195895/0001193125-24-195895-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312524195895/d880974d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-195895

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer